Peak plasma concentrations are reached 3 to 4 hours after oral administration; bioavailability: poorly absorbed from the gastrointestinal tract (5%).
Metabolism: CYP3A4 extensively metabolizes to both active and inactive metabolites in the liver.
18 hours is the half-life.
Urine (84%) and feces (11%) are excreted.
The most frequent side effects of Altace are dry cough, headache, and dizziness. Additional negative effects include:
the following uncommon but severe side effects:
Patients should be instructed to notify their doctor right away if they experience any angioedema symptoms, such as swelling of the face, lips, tongue, or throat, as well as trouble breathing or swallowing, or hepatotoxicity symptoms, such as jaundice, dark urine, clay-colored stools, itching, or pain in the right upper quadrant.
Dosage and Administration
For oral administration, Altace comes in 2.5 mg, 5 mg, and 10 mg capsules. 2.5 mg administered once daily is the suggested starting dose. Depending on how the patient's blood pressure responds, the dosage may be increased to a maximum of 10 mg once daily.
2.5 mg once daily is the suggested starting dose for patients with mild-to-moderate hepatic impairment. According to the patient's response in terms of blood pressure, the dosage should be changed.
Patients need to be instructed to take Altace every day at the same time, with or without food. No opening, crushing, or chewing of capsules is permitted.
Overdose symptoms include:
Storage and Handling
Altace capsules should be stored at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F).
Dispense in a tight, light-resistant container as defined in the USP.